Media headlines about AveXis (NASDAQ:AVXS) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AveXis earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.0373831285401 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- AveXis (AVXS) Reports Licensing Agreement with Genethon (streetinsider.com)
- AveXis (AVXS) Receives Buy Rating from William Blair (americanbankingnews.com)
- BRIEF-Avexis Enters Into Licensing Agreement With Genethon (reuters.com)
- AveXis Enters into Licensing Agreement with Genethon (finance.yahoo.com)
- AveXis (AVXS) Raised to “Strong-Buy” at BidaskClub (americanbankingnews.com)
AveXis (AVXS) opened at $134.41 on Thursday. The stock has a market cap of $4,940.00 and a PE ratio of -18.64. AveXis has a 52-week low of $65.23 and a 52-week high of $138.46.
Several analysts recently commented on AVXS shares. BMO Capital Markets reiterated a “buy” rating on shares of AveXis in a research note on Monday, January 8th. Chardan Capital reiterated a “buy” rating and issued a $135.00 price objective on shares of AveXis in a research note on Friday, January 5th. Morgan Stanley set a $120.00 price objective on shares of AveXis and gave the company a “buy” rating in a research note on Friday, January 5th. UBS Group set a $122.00 price objective on shares of AveXis and gave the company a “buy” rating in a research note on Friday, January 5th. Finally, Citigroup set a $132.00 price objective on shares of AveXis and gave the company a “buy” rating in a research note on Friday, January 5th. Three analysts have rated the stock with a sell rating, three have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $123.90.
In other news, CEO Sean P. Nolan sold 10,000 shares of AveXis stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $129.47, for a total transaction of $1,294,700.00. Following the completion of the sale, the chief executive officer now directly owns 10,000 shares in the company, valued at $1,294,700. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP James J. Litalien sold 5,000 shares of AveXis stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $106.52, for a total transaction of $532,600.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,560 shares of company stock valued at $7,793,030. 18.60% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by BBNS and is owned by of BBNS. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://baseballnewssource.com/2018/03/15/avexis-avxs-receiving-somewhat-positive-media-coverage-report-shows/2034845.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.